Skip to content
Screener

ImmunityBio, Inc. IBRX Other revenues — Total Revenue

Similar metrics at other companies

PTH
PTHSNet product revenues — Total Revenue
$10.67M
Life Time Group Holdings logo
LTHOther revenue — Total Revenue
$28.59M+11.7%
Sirius XM logo
SIRIOther revenue — Total Revenue
$68M-11.7%
Moderna logo
MRNAOther revenue — Total Revenue
$37M+68.2%
GeneDx Holdings logo
WGSOther revenue — Total Revenue
$955K-29.6%
Snap logo
SNAPOther revenue — Total Revenue
$316.47M+84.7%

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.68B+242%
Enterprise value$7.92B+227%
P/S54.5×+14.8×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:37 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001326110-26-000059
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Revenue
Product revenue, net$44,167$16,509
Other revenues398
Total revenue44,20616,517
Operating costs and expenses
Cost of sales23858
Research and development64,77045,976
Research and development – related parties3,2192,258

ITEM 1. FINANCIAL STATEMENTS.

FAQ

What is ImmunityBio, Inc.'s other revenues — total revenue?
ImmunityBio, Inc. (IBRX) reported other revenues — total revenue of $39K in Q1 2026.
How has ImmunityBio, Inc.'s other revenues — total revenue changed year-over-year?
ImmunityBio, Inc.'s other revenues — total revenue increased by 387.5% year-over-year, from $8K to $39K.
What is the long-term trend for ImmunityBio, Inc.'s other revenues — total revenue?
Over 3 years (2022 to 2025), ImmunityBio, Inc.'s other revenues — total revenue has grown at a 8.4% compound annual growth rate (CAGR), from $240K to $306K.
What does other revenues — total revenue mean?
This metric represents the aggregate revenue generated from business activities outside of the company's primary therapeutic product lines or core commercialized treatments. It typically encompasses ancillary income streams such as contract research services, licensing fees, or collaborative development arrangements that do not constitute the main revenue-generating focus. Tracking this figure helps investors understand the contribution of secondary business segments to the company's overall financial performance.

Ask your AI about ImmunityBio, Inc.'s other revenues — total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude